// App-Quantinova.ai

: An Ex-Vivo Combination Drug Sensitivity Platform for Predicting Sensitivity to FLT3 Inhibitor-Based Combination in Acute Myeloid Leukemia

Researchers

Presenter

  • Noor Rashidha Binte Meera Sahib

Principal Investigators

  • Jen Wei Ying

  • Melissa Ooi

  • Yen Lin Chee

  • Masturah Rashid

  • Jayalakshmi Jayalakshmi

  • Edward KH Chow

Medical Centers

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

  • Department of Haematology Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore

  • Cancer Science Institute of Singapore, National University of Singapore, Singapore, SGP

  • National University Health System, Singapore, Singapore

  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore, Singapore

  • KYAN Therapeutics, Singapore, Singapore

Locations

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 34

Drug/Treatment

  • gilteritinib

  • Midostaurin

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved